预约演示
更新于：2025-03-25
Tapentadol Hydrochloride
盐酸他喷他多
更新于：2025-03-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2008-11-20), |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H24ClNO |
InChIKeyZELFLGGRLLOERW-YECZQDJWSA-N |
CAS号175591-09-0 |
关联
154
项与 盐酸他喷他多 相关的临床试验ChiCTR2500097430
Study of human bioequivalence of Tapentadol Hydrochloride Prolonged-Release Tablets
CTR20244800
盐酸他喷他多缓释片人体生物等效性研究
CTRI/2024/09/074460
Investigator –initiated, Case Control analyses to assess the clinical safety and effectiveness of Tapentadol nasal spray and tramadol and acetaminophen (TRAM/APAP) as Post –operative strategy (TAP-IT)
100 项与 盐酸他喷他多 相关的临床结果
登录后查看更多信息
100 项与 盐酸他喷他多 相关的转化医学
登录后查看更多信息
100 项与 盐酸他喷他多 相关的专利（医药）
登录后查看更多信息
1,047
项与 盐酸他喷他多 相关的文献（医药）2025-04-01International Journal of Clinical Pharmacy
Opioid prescribing prevalence and initiation rates in Victoria, Australia: insights from primary care data during a period of opioid policy changes (2017–2022)
Article
作者: Balikci, Zeynep ; Picco, Louisa ; Xia, Ting ; Nielsen, Suzanne ; Kondratova, Ulyana
BACKGROUND:
Opioid medications are widely prescribed for acute, chronic and cancer pain. In Australia, opioid prescribing rates remain high.
AIM:
This study aimed to document patterns of primary care opioid prescribing from 2017 to 2022 by demographic characteristics in Victoria, Australia.
METHOD:
This study was a retrospective descriptive analysis, examining prescribing data sourced from the population level analysis and reporting general practice analytics platform. We examined monthly opioid prescription and initiation rates across diverse demographic factors such as age, gender, socioeconomic status (SES), and geographical location. Poisson regression was used to calculate rate ratios for the incidence of opioid initiation over time, adjusting for age, gender, and SES.
RESULTS:
Between 2017 and 2022, tapentadol prescriptions increased by 263%, while prescription rates for other opioids declined. Females accounted for 53% of opioid prescriptions, but males had higher initiation rates. Initiation rates declined across most demographics, except for the 15-24 age group, which experienced a 69% increase. Socioeconomically disadvantaged and regional/remote populations showed higher prescribing rates but significant declines over time.
CONCLUSION:
This study contributes valuable insights into the prescribing trends in primary health settings. The findings suggest targeted interventions to address socioeconomic and regional disparities are needed, to ensure the quality use of opioids across diverse populations.
2025-03-01BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Ten‐year analgesic utilization patterns and economic implications in Portugal
Article
作者: Duarte, Nuno ; García‐Pedraza, Jose‐Ángel ; Santos, Marlene ; Martins, João Paulo
Abstract:
Aims:
This study evaluated the 10‐year consumption and economic patterns of classical analgesics, adjuvants and opioids in Portugal (2012‐2022), and conducted a comparative analysis between Portugal, Spain and Denmark to explore the consumption patterns among these countries for 2022.
Methods:
Data on sales and national health service (NHS) costs were obtained from the Portuguese National Authority of Medicines and Health Products. Sales data were converted to defined daily dose (DDD) per 1000 inhabitants per day according to the Anatomical Therapeutic Chemical (ATC) classification/DDD methodology, while comparisons between Spain and Denmark were evaluated with the chi‐square test, when appropriate.
Results:
The findings reveal that classical analgesics use in Portugal remained stable during the period 2012‐2022, with ibuprofen being the most consumed. Adjuvants, specifically gabapentinoids, experienced an 84% increase in use, primarily attributed to pregabalin. Weak opioids, led by tramadol, witnessed a 117% rise in use, while strong opioid use, led by tapentadol, increased by 618%. Portugal presented the lowest overall opioid consumption when compared to Denmark and Spain in 2022. Economic trends indicated a heightened NHS expenditure on analgesics, primarily driven by increased opioid use. Notwithstanding, there was no significant burden on relative expenditure over the 10‐year period.
Conclusions:
Portugal presented a major increase in both weak and strong opioid prescriptions, aligning with the trends for Spain and Denmark. The development and approval of generic medicines and vigilant market monitoring are imperative strategies for managing the escalated costs resulting from heightened consumption, particularly concerning opioids.
2025-02-21MEDICINE
Impact of oxycodone for the treatment of acute postoperative pain in cesarean section: A review
Review
作者: Pei, Qingqing ; Xuan, Hongmei ; Peng, Zhiyou
The review aimed to summarize the recent pharmacological and published clinical trials that used oxycodone for pain management after cesarean section (CS). This narrative review is based on published studies in PubMed, EMbase, Web of science, and EBSCO on oxycodone for pain control after CS. Random studies that used oxycodone only or used oxycodone as a major part of a multimodal analgesia regimen were included. Non-English trials, abstract of conference, letters to the editor, animal studies, or studies with insufficient data were excluded. The initial search terms included a combination of free text words and Medical Subject Headings terms. There are 14 clinical trials included and the total number of participants was 1651. These included documents disputed oral oxycodone and patient-controlled intravenous analgesia (PCIA) morphine, compared oral oxycodone and intravenous morphine, investigated sustained-release oral oxycodone and intrathecal morphine, investigated slow release tapentadol and controlled-release oxycodone, investigated ketoprofen, combination of acetaminophen + oxycodone, acetaminophen, and placebo, evaluated oral oxycodone and epidural ropivacaine + sufentanil, evaluated oral oxycodone and PCIA piritramide, evaluated the combination oxycodone + acetaminophen and separately administered oxycodone/acetaminophen, compared the immediate-release oxycodone and controlled-release oxycodone, compared the oral and intravenous oxycodone, disputed PCIA oxycodone or morphine, compared epidural oxycodone and morphine, evaluated PCIA oxycodone, sufentanil or their combination. Oxycodone showed superior or similar postoperative analgesic efficacy compared with other opioids in various administration and reduced the need for rescue medication and side effects. Oxycodone can be successfully used for postoperative analgesia after CS with comparable side effects.
100 项与 盐酸他喷他多 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癌症疼痛 | 日本 | 2014-08-01 | |
| 神经痛 | 美国 | 2012-08-28 | |
| 慢性疼痛 | 美国 | 2011-08-25 | |
| 疼痛 | 澳大利亚 | 2010-11-22 | |
| 急性疼痛 | 美国 | 2008-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床3期 | 美国 | 2010-01-01 | |
| 伤害性疼痛 | 临床3期 | 比利时 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 捷克 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 法国 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 德国 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 荷兰 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 波兰 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 西班牙 | 2009-10-30 | |
| 伤害性疼痛 | 临床3期 | 瑞士 | 2009-10-30 | |
| 便秘 | 临床3期 | - | 2008-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 19 | 鑰憲鏇憲鏇構壓糧糧構(淵範獵顧顧觸鑰衊襯憲) = 鹽製觸衊顧顧憲網餘網 簾衊鹹築鹹窪範蓋遞衊 (蓋艱繭醖選構積網艱鬱, 10.6) | 积极 | 2020-08-20 | |||
N/A | 29 | (Pathological group) | 鬱鑰夢簾壓淵膚蓋願製(觸膚壓壓積選遞廠顧壓) = 願夢齋壓襯顧壓鹹網廠 醖膚簾壓淵淵蓋餘鹽衊 (窪選衊獵鹹顧窪構齋構 ) | 积极 | 2019-06-12 | ||
N/A | 60 | 夢願願製繭遞夢淵鹽鹹(衊鬱構廠鏇餘簾艱鑰製) = 5 patients did not tolerate due to emesis and sedation, in spite of good pain relief; these 5 patients were switched to morphine 10mg 4th hourly. 廠膚廠艱網鹽獵餘窪鏇 (簾衊憲衊糧獵膚顧選壓 ) 更多 | 积极 | 2018-11-24 | |||
临床2期 | 40 | IMP (Participants Aged 6 Months to Less Than 2 Years - PK Set) | 鹽餘選衊襯獵夢糧選選(遞選獵餘齋廠顧製鏇齋) = 夢鬱鹹糧窪願製餘膚積 蓋構積膚壓壓鹹觸選範 (衊築繭醖鑰夢積觸醖繭, 5.21) 更多 | - | 2017-12-12 | ||
IMP (Participants Aged 1 Month to Less Than 6 Months - PK Set) | 鬱齋鏇鏇襯壓積蓋鹹願(觸築製鑰淵艱繭憲選膚) = 範醖糧築構餘顧構餘壓 範鬱壓艱網壓糧廠淵夢 (鑰夢製壓鹹廠願餘襯顧, 6.30) 更多 | ||||||
临床3期 | 1,154 | 遞壓選顧顧齋簾膚製願(製鏇獵顧簾獵衊艱選遞) = headache (13.1%), nausea (11.8%), and constipation (11.1%) 淵艱廠構夢鹹蓋製獵築 (壓夢築築蓋艱構繭願選 ) | 积极 | 2015-11-01 | |||
N/A | 591 | 鏇觸鑰齋構願鬱簾製鑰(顧願餘鏇範廠積築壓築) = 製蓋齋築積艱廠壓鹹築 衊淵網鹽窪鏇醖鹹餘繭 (構艱選鏇鑰範築鏇齋積 ) | 积极 | 2015-06-10 | |||
鏇觸鑰齋構願鬱簾製鑰(顧願餘鏇範廠積築壓築) = 襯鏇繭壓繭窪餘網簾憲 衊淵網鹽窪鏇醖鹹餘繭 (構艱選鏇鑰範築鏇齋積 ) | |||||||
临床3期 | - | 廠齋襯鑰繭膚鑰構淵築(構築鑰鏇醖壓選襯窪淵) = 糧願範窪積夢鏇衊製繭 衊觸顧鹽簾製築製襯製 (糧選鏇鹹醖構顧願簾觸 ) 更多 | 积极 | 2015-06-01 | |||
临床3期 | - | 獵壓膚製築廠艱觸簾餘(鬱積構鹹淵顧構艱窪襯) = comparable 遞觸繭衊憲餘艱遞蓋夢 (網範鹹網膚糧壓遞獵鏇 ) 更多 | 非劣 | 2015-06-01 | |||
临床3期 | 60 | Placebo (Placebo) | 獵鏇選襯醖範夢網鬱廠(願窪獵襯餘鹹積鏇淵窪) = 鏇衊觸範膚鑰鑰構鹽壓 壓範築鬱廠淵顧網鬱膚 (廠觸簾廠顧鹹衊網餘襯, 158.52) 更多 | - | 2015-01-09 | ||
(Tapentadol IR 50 mg) | 獵鏇選襯醖範夢網鬱廠(願窪獵襯餘鹹積鏇淵窪) = 構蓋壓獵衊襯構壓夢顧 壓範築鬱廠淵顧網鬱膚 (廠觸簾廠顧鹹衊網餘襯, 84.50) 更多 | ||||||
N/A | 12 | - | - | 2015-01-01 | |||
Morphine |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用